Systems biology evaluation of cell-free amniotic fluid transcriptome of term and preterm infants to detect fetal maturity

BMC Medical Genomics

Yan Xu²  Nathan Salomonis²  Jeffrey A. Whitsett¹  Emily A. DeFranco³  Louis J. Muglia¹  Erin A. Wagner¹  Maria Hughes¹  Yina Du¹  Beena D. Kamath-Rayne¹ 

[1] Perinatal Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA;Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA;Maternal-Fetal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA

关键词: Prenatal diagnosis;    Transcriptome;    Fetal lung maturity;    Amniotic fluid;   

Others  :  1233849
DOI  :  10.1186/s12920-015-0138-5

 received in 2015-06-05, accepted in 2015-09-23,  发布年份 2015

【 摘 要 】

Background

Amniotic fluid (AF) is a proximal fluid to the fetus containing higher amounts of cell-free fetal RNA/DNA than maternal serum, thereby making it a promising source for identifying novel biomarkers that predict fetal development and organ maturation. Our aim was to compare AF transcriptomic profiles at different time points in pregnancy to demonstrate unique genetic signatures that would serve as potential biomarkers indicative of fetal maturation.

Methods

We isolated AF RNA from 16 women at different time points in pregnancy: 4 from 18 to 24 weeks, 6 from 34 to 36 weeks, and 6 from 39 to 40 weeks. RNA-sequencing was performed on cell-free RNA. Gene expression and splicing analyses were performed in conjunction with cell-type and pathway predictions.

Results

Sample-level analysis at different time points in pregnancy demonstrated a strong correlation with cell types found in the intrauterine environment and fetal respiratory, digestive and external barrier tissues of the fetus, using high-confidence cellular molecular markers. While some RNAs and splice variants were present throughout pregnancy, many transcripts were uniquely expressed at different time points in pregnancy and associated with distinct neonatal co-morbidities (respiratory distress and gavage feeding), indicating fetal immaturity.

Conclusion

The AF transcriptome exhibits unique cell/organ-selective expression patterns at different time points in pregnancy that can potentially identify fetal organ maturity and predict neonatal morbidity. Developing novel biomarkers indicative of the maturation of multiple organ systems can improve upon our current methods of fetal maturity testing which focus solely on the lung, and will better inform obstetrical decisions regarding delivery timing.

【 授权许可】

   
2015 Kamath-Rayne et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Kamath-Rayne BD, Smith HC, Muglia LJ, Morrow AL: Amniotic fluid: the use of high-dimensional biology to understand fetal well-being. Reprod Sci 2014, 21(1):6-19.
• [2]Hui L, Slonim DK, Wick HC, Johnson KL, Bianchi DW: The amniotic fluid transcriptome: a source of novel information about human fetal development. Obstet Gynecol 2012, 119(1):111-118.
• [3]Kang JH, Park HJ, Jung YW, Shim SH, Sung SR, Park JE, Cha DH, Ahn EH: Comparative transcriptome analysis of cell-free fetal RNA from amniotic fluid and RNA from amniocytes in uncomplicated pregnancies. PLoS One 2015, 10(7):e0132955.
• [4]Hui L, Wick HC, Edlow AG, Cowan JM, Bianchi DW: Global gene expression analysis of term amniotic fluid cell-free fetal RNA. Obstet Gynecol 2013, 121(6):1248-1254.
• [5]Zwemer LM, Bianchi DW. The amniotic fluid transcriptome as a guide to understanding fetal disease. Cold Spring Harb Perspect Med. 2015;5(4). doi:10.1101/cshperspect.a023101.
• [6]Kamath B, Marcotte M, DeFranco E: Neonatal morbidity after documented fetal lung maturity in late preterm and early term infants. Am J Obstet Gynecol 2011, 204:518.e511-e518.
• [7]Bates E, Rouse D, Mann M, Chapman V, Carlo W, Tita A: Neonatal outcomes after demonstrated fetal lung maturity before 39 weeks gestation. Obstet Gynecol 2010, 116(6):1288-1295.
• [8]Graca G, Duarte IF, Barros AS, Goodfellow BJ, Diaz SO, Pinto J, Carreira IM, Galhano E, Pita C, Gil AM: Impact of prenatal disorders on the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J Proteome Res 2010, 9(11):6016-6024.
• [9]Towers CV, Freeman RK, Nageotte MP, Garite TJ, Lewis DF, Quilligan EJ: The case for amniocentesis for fetal lung maturity in late-preterm and early-term gestations. Am J Obstet Gynecol 2014, 210(2):95-96.
• [10]Gregg AR, Van den Veyver IB, Gross SJ, Madankumar R, Rink BD, Norton ME: Noninvasive prenatal screening by next-generation sequencing. Annu Rev Genomics Hum Genet 2014, 15:327-347.
• [11]McGinnis K, Brown J, Morrison J: Changing patterns of fetal lung maturity testing. J Perinatol 2008, 28:20-23.
• [12]Kolialexi A, Tounta G, Mavrou A, Tsangaris GT: Proteomic analysis of amniotic fluid for the diagnosis of fetal aneuploidies. Expert Rev Proteomics 2011, 8(2):175-185.
• [13]Cho CK, Shan S, Winsor E, Diamandis E: Proteomics analysis of human amniotic fluid. Mol Cell Proteomics 2007, 6(8):1406-1415.
• [14]Bianchi DW, LeShane ES, Cowan JM: Large amounts of cell-free fetal DNA are present in amniotic fluid. Clin Chem 2001, 47(10):1867-1869.
• [15]Dietz JA, Johnson KL, Massingham LJ, Schaper J, Horlitz M, Cowan J, Bianchi DW: Comparison of extraction techniques for amniotic fluid supernatant demonstrates improved yield of cell-free fetal RNA. Prenat Diagn 2011, 31(6):598-599.
• [16]García-Escudero LÁ, Gordaliza A: Robustness properties of k means and trimmed k means. J Am Stat Assoc 1999, 94(447):956-969.
• [17]Emig D, Salomonis N, Baumbach J, Lengauer T, Conklin BR, Albrecht M: AltAnalyze and DomainGraph: analyzing and visualizing exon expression data. Nucleic Acids Res 2010, 38(Web Server issue):W755-762.
• [18]Zambon AC, Gaj S, Ho I, Hanspers K, Vranizan K, Evelo CT, Conklin BR, Pico AR, Salomonis N: GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics (Oxford, England) 2012, 28(16):2209-2210.
• [19]Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, et al.: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004, 101(16):6062-6067.
• [20]Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, et al.: Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002, 8(7):702-710.
• [21]Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, et al.: Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A 2010, 107(4):1431-1436.
• [22]Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, et al.: The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell 2010, 18(4):579-591.
• [23]Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al.: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25(1):25-29.
• [24]American College of Obstetricians and Gynecologists. Fetal lung maturity. ACOG Practice Bulletin Number 97, replaces Educational Bulletin Number 230. 2008.
• [25]Fang YM, Guirguis P, Borgida A, Feldman D, Ingardia C, Herson V: Increased neonatal morbidity despite pulmonary maturity for deliveries occurring before 39 weeks. J Matern Fetal Neonatal Med 2013, 26(1):79-82.
• [26]Vanderhoeven JP, Peterson SE, Gannon EE, Mayock DE, Gammill HS: Neonatal morbidity occurs despite pulmonary maturity prior to 39 weeks gestation. J Perinatol 2014, 34(4):322-325.
• [27]The American College of Obstetricians and Gynecologists Committee on Obstetric PracticeThe Society for Maternal-Fetal Medicine: ACOG committee opinion no. 560: medically indicated late-preterm and early-term deliveries Obstet Gynecol 2013, 121(4):908-910.
• [28]Varner S, Sherman C, Lewis D, Owens S, Bodie F, McCathran CE, Holliday N: Amniocentesis for fetal lung maturity: will it become obsolete? Rev Obstet Gynecol 2013, 6(3–4):126-134.
• [29]Raju TN: Moderately preterm, late preterm and early term infants: research needs. Clin Perinatol 2013, 40(4):791-797.
• [30]Raju TN, Higgins RD, Stark AR, Leveno KJ: Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics 2006, 118(3):1207-1214.
• [31]Green NS, Damus K, Simpson JL, Iams J, Reece EA, Hobel CJ, Merkatz IR, Greene MF, Schwarz RH: Research agenda for preterm birth: recommendations from the March of Dimes. Am J Obstet Gynecol 2005, 193(3 Pt 1):626-635.
• [32]Zwemer LM, Hui L, Wick HC, Bianchi DW: RNA-Seq and expression microarray highlight different aspects of the fetal amniotic fluid transcriptome. Prenat Diagn 2014, 34(10):1006-1014.
• [33]Edlow AG, Vora NL, Hui L, Wick HC, Cowan JM, Bianchi DW: Maternal obesity affects fetal neurodevelopmental and metabolic gene expression: a pilot study. PLoS One 2014, 9(2):e88661.